Related Experiment Video

Updated: Aug 14, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Targeting cytokines beyond tumor necrosis factor-alpha and interleukin-1 in rheumatoid arthritis

Iain B McInnes1, J Alastair Gracie

  • 1Centre for Rheumatic Diseases, Glasgow Royal Infirmary, 10 Alexandra Parade, Glasgow, G31 2ER, Scotland. i.b.mcinnes@clinmed.gla.ac.uk

Current Pain and Headache Reports
|November 12, 2005
PubMed

Insights

New biologic targets like interleukin-6 (IL-6) and others show promise for rheumatoid arthritis patients who do not respond well to tumor necrosis factor-alpha (TNF-a) therapies, addressing a significant unmet clinical need.

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • Tumor necrosis factor-alpha (TNF-a) inhibitors are valuable for rheumatoid arthritis (RA) but offer insufficient benefits for many patients.
  • A significant unmet clinical need exists for RA patients with inadequate responses to current therapies.
  • Several proinflammatory cytokines, including IL-6, IL-12, IL-15, and IL-18, are implicated in RA synovitis.

Purpose of the Study:

  • To review recent data on the therapeutic potential of novel cytokines in rheumatoid arthritis.
  • To explore the utility of these cytokines as alternative or synergistic treatments for RA.
  • To identify potential treatments for patients with partial responses to TNF-a inhibitors.

Main Methods:

  • Review of recent scientific literature and clinical data.
  • Analysis of the role of specific cytokines (IL-6, IL-12, IL-15, IL-18) in RA pathogenesis.
  • Evaluation of therapeutic strategies involving these cytokines.

Main Results:

  • Emerging data suggest IL-6, IL-12, IL-15, and IL-18 possess proinflammatory activity in RA.
  • These cytokines demonstrate potential as therapeutic targets for RA management.
  • Consideration of their use in patients with suboptimal response to TNF-a blockade.

Conclusions:

  • Novel cytokine-targeting therapies offer potential for rheumatoid arthritis treatment.
  • Interleukin-6 and other cytokines may benefit RA patients non-responsive to TNF-a inhibitors.
  • Synergistic or alternative therapeutic approaches using these cytokines warrant further investigation.

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...